Lung cancer drug hope; BRITAIN BRIEFLY.
A drug that frees the immune system to attack a devastating form of lung cancer has been shown to double the life expectancy of targeted patients.
Nivolumab is one of a new generation of immunotherapy drugs. The results, from a major trial involving patients who had already been treated for the most common form of lung cancer, were described by one expert as a "paradigm shift".
In the Phase III trial, the last step before a drug is licensed, the drug was found to be most effective in patients whose cancers produced higher levels of a protein PD-L1, which could lead to personalised treatment.